Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Antiangiogenic combination therapy
2 evidence topics · 2 sources
Ivonescimab
EGFR-mutated non-small-cell lung cancer
- Manufacturer
- Summit Therapeutics
- Regulatory submission
- BLA submitted in the fourth quarter of 2025
- Launch
- Not announced
- Last updated